Related Experiment Videos
Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive,
1Infectious Diseases Laboratory, San Francisco General Hospital, and Departments of Medicine and Neurology, University of California, San Francisco, San Francisco, California 94143-0811, USA.
Abstract:
The new fluoroquinolone trovafloxacin was tested against a ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus strain in the rabbit model of endocarditis. Trovafloxacin was more effective than vancomycin (CFU/g of vegetation, 2.65 +/- 1.87 versus 4.54 +/- 2.80 [mean +/- standard deviation]; P < 0.05) or ampicillin-sulbactam plus rifampin (4.9 +/- 1.1 CFU/g). The addition of ampicillin-sulbactam to trovafloxacin tended to reduce titers further.
Insights
The novel fluoroquinolone trovafloxacin demonstrated superior efficacy against methicillin-resistant Staphylococcus aureus endocarditis in rabbits compared to vancomycin and ampicillin-sulbactam plus rifampin.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat in healthcare settings.
- Bacterial endocarditis is a severe infection requiring effective antimicrobial therapy.
- Novel antibiotics are needed to combat resistant bacterial strains.
Purpose of the Study:
- To evaluate the efficacy of trovafloxacin against a specific MRSA strain in a rabbit model of endocarditis.
- To compare trovafloxacin's effectiveness with established antibiotics like vancomycin and combination therapy.
Main Methods:
- A rabbit model of endocarditis was utilized.
- Infection was established with a ciprofloxacin-sensitive, MRSA strain.
- Treatment groups included trovafloxacin, vancomycin, and ampicillin-sulbactam plus rifampin.
Main Results:
- Trovafloxacin showed significantly greater efficacy than vancomycin (P < 0.05).
- Trovafloxacin was also more effective than ampicillin-sulbactam plus rifampin.
- Combining ampicillin-sulbactam with trovafloxacin suggested a trend towards further bacterial titer reduction.
Conclusions:
- Trovafloxacin is a highly effective agent against MRSA endocarditis in this preclinical model.
- Trovafloxacin represents a promising therapeutic option for MRSA infections.
- Further investigation into combination therapies may enhance treatment outcomes.